Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PPQK | ISIN: US4495851085 | Ticker-Symbol: 1K0
Frankfurt
31.03.25
16:08 Uhr
1,050 Euro
-0,070
-6,25 %
1-Jahres-Chart
IGM BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
IGM BIOSCIENCES INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,0501,09022:01
1,0501,09022:00

Aktuelle News zur IGM BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07.03.Stifel maintains IGM Biosciences stock hold with $2.50 target4
06.03.IGM Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
06.03.IGM Biosciences, Inc. - 10-K, Annual Report1
10.01.IGM Bio plunges as Wall Street downgrades on portfolio shakeup14
IGM BIOSCIENCES Aktie jetzt für 0€ handeln
10.01.IGM Biosciences halts development of auto-immune treatments, shares plummet18
09.01.IGM Biosciences Halts Development Of Imvotamab, IGM-2644; To Lay Off 73% Of Workforce7
09.01.IGM Biosciences cuts workforce, halts a couple of product developments7
09.01.IGM Biosciences, Inc.: IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs154- Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) - - Company reducing its workforce by 73% - - Cash and investments of $183.8 million (unaudited) as of December...
► Artikel lesen
09.11.24IGM Biosciences (NASDAQ:IGMS) Stock Price Down 7.8% - Here's Why5
08.11.24IGM Biosciences, Inc.: IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update166- Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 - - IGM-2644 (CD38 x CD3) expected to enter...
► Artikel lesen
08.11.24IGM Biosciences, Inc. - 8-K, Current Report-
08.11.24IGM Biosciences, Inc. - 10-Q, Quarterly Report-
28.10.24IGM Biosciences (NASDAQ:IGMS) Trading Up 7.7% - Here's What Happened1
24.10.24IGM Biosciences' SWOT analysis: autoimmune pivot drives stock outlook1
18.10.24IGM Biosciences stock target increased on autoimmune pivot1
11.10.24IGM Biosciences (NASDAQ:IGMS) Trading 8.1% Higher - Here's Why3
04.10.24IGM Biosciences (NASDAQ:IGMS) Trading 10.1% Higher - Here's What Happened2
03.10.24IGM Biosciences, Inc. - 8-K, Current Report4
01.10.24Pre-market Movers: Shattuck Labs, SITE Centers, IGM Biosciences, ATIF Holdings, Arqit Quantum745OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.45 A.M. ET).In the Green SITE Centers Corp. (SITC) is up over 53% at $18.12. ATIF...
► Artikel lesen
30.09.24IGM Biosciences, Inc.: IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity321- Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and systemic lupus erythematosus - - Mary...
► Artikel lesen
Seite:  Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1